Kok END, Havenga K, Tanis PJ, et al. - Researchers examined if short‐course pelvic radiotherapy (5 × 5 Gy) followed by systemic therapy and local treatment is feasible and effective for managing all tumor sites in patients with potentially curable stage IV rectal cancer in daily practice. In this retrospective study, 169 patients were included from eight tertiary referral centers in the Netherlands; the median follow‐up period was 49·5 months. The entire treatment schedule was completed by 65·7%. Three‐year progression‐free survival rate was 24·2% and overall survival (OS) rate was 48·8%, respectively. Patients who responded well and completed the treatment schedule had median OS of 51·5 months vs 15·1 months for patients who did not complete the treatment. In 87·0% of all patients, the primary tumor symptoms were adequately controlled. Findings suggest that symptoms in most patients could be relieved with multimodal treatment, and good survival rates among those who were able to complete the schedule.